Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects

ConclusionImeglimin was safe and well tolerated in these two phases 1 studies, with pharmacokinetics comparable between the two populations.Clinical Trial RegistrationsEudraCT 2005-001946-18 and 2014-004679-21.

Source: Clinical Drug Investigation - July 22, 2022 Category: Drugs & Pharmacology Source Type: research